We propose to demonstrate that HIV-1 and SARS-CoV-2 are capable of targeting long-lived HSPC with self-renewal capacities. These progenitors, thus transformed into host cells, can give rise to a durable source of infected cells with an impact on hematopoiesis.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
HIV patients :
* HIV-positive patients with a negative or positive viral load.
* managed at Ambroise Paré Hospital.
* patients with a bone marrow biopsy or myelogram performed as part of their care.
Healthy subjects without HIV - patients with a BM biopsy or myelogram performed as part of their care for a suspected hematological pathology.
Management at Ambroise Paré Hospital.
Exclusion Criteria:
\-
Primary outcome measure(s)
Evaluate if infected HSPC would modulate the bone marrow environment — at 1 year Evaluate whether these infected HSPC would modulate the bone marrow environment by upregulating inflammatory cytokines detrimental to lymphopoiesis.
Trial sites (1)
Facility
City
Region
Status
Hematology and interne medicine department, Ambroise Paré hospital - APHP
Boulogne-Billancourt
France
Recruiting
More Assistance Publique - Hôpitaux de Paris trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
